CD14+CD16+ and CD14+CD163+ monocyte subpopulations in kidney allograft transplantation

BMC Immunology

Ilja Striz²  Vera Lanska⁴  Ondrej Viklicky¹  Janka Slatinska¹  Eva Brabcova²  Eva Krepsova³  Alena Sekerkova² 

[1] Department of Nephrology, Transplant Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic;Department of Clinical and Transplant Immunology, Institute for Clinical and Experimental Medicine, Videnska 1958/9, Prague 4 140 21, Czech Republic;Transplant Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czech Republic;Department of Statistics, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

关键词: Transplantation;    Subpopulations;    Monocytes;    Kidney;    CD14+CD163+;    CD14+CD16+;   

Others  :  1077731
DOI  :  10.1186/1471-2172-15-4

 received in 2013-07-19, accepted in 2014-01-29,  发布年份 2014

【 摘 要 】

Background

Monocytes represent a heterogeneous population of cells subdivided according to the expression level of membrane antigens. A pro-inflammatory (intermediate/nonclassical) subpopulation of monocytes is defined by expression of CD16. CD163 seems to be characteristically preferentially expressed by immunosuppressive monocytes. The aim of our study was to evaluate the distribution of monocyte subpopulations in 71 patients with kidney allograft transplantation.

Results

The phenotype was evaluated by flow cytometry in defined time points. The proportions of peripheral CD14+CD16+ monocytes were downregulated immediately after the kidney transplantation and basiliximab treatment partially attenuated this trend. The transient downregulation of the CD14+CD16+ subpopulation was adjusted to basal values in two months. The proportions of CD14+CD163+ monocytes were transiently upregulated early after the kidney transplantation and remained higher during the first month in most patients. In ATG treated patients, the expansion of CD14+CD163+ monocytes was delayed but their upregulation lasted longer. In vitro data showed the direct effect of ATG and methylprednisolone on expression of CD16 and CD163 molecules while basiliximab did not affect the phenotype of cultured monocytes.

Conclusions

We assume from our data that kidney allograft transplantation is associated with modulation of monocyte subpopulations (CD14+CD16+ and CD14+CD163+) partially affected by an immunosuppressive regime used.

【 授权许可】

   
2014 Sekerkova et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 2.

Figure 8.

【 参考文献 】

• [1]Girlanda R, Kleiner DE, Duan Z, Ford EA, Wright EC, Mannon RB, Kirk AD: Monocyte infiltration and kidney allograft dysfunction during acute rejection. Am J Transplant 2008, 8(3):600-607.
• [2]Hribova P, Lacha J, Kotsch K, Volk HD, Brabcova I, Skibova J, Vitko S, Viklicky O: Intrarenal cytokine and chemokine gene expression and kidney graft outcome. Kidney Blood Press Res 2007, 30(5):273-282.
• [3]Passlick B, Flieger D, Ziegler-Heitbrock HW: Identification and characterization of a novel monocyte subpopulation in human peripheral blood. Blood 1989, 74(7):2527-2534.
• [4]Ziegler-Heitbrock L: The CD14+ CD16+ blood monocytes: their role in infection and inflammation. J Leukoc Biol 2007, 81(3):584-592. Epub 2006 Nov 2029
• [5]Ziegler-Heitbrock HW, Strobel M, Fingerle G, Schlunck T, Pforte A, Blumenstein M, Haas JG: Small (CD14+/CD16+) monocytes and regular monocytes in human blood. Pathobiology 1991, 59(3):127-130.
• [6]Komohara Y, Hirahara J, Horikawa T, Kawamura K, Kiyota E, Sakashita N, Araki N, Takeya M: AM-3K, an anti-macrophage antibody, recognizes CD163, a molecule associated with an anti-inflammatory macrophage phenotype. J Histochem Cytochem 2006, 54(7):763-771. Epub 2006 Mar 2003
• [7]Weber C, Belge KU, von Hundelshausen P, Draude G, Steppich B, Mack M, Frankenberger M, Weber KS, Ziegler-Heitbrock HW: Differential chemokine receptor expression and function in human monocyte subpopulations. J Leukoc Biol 2000, 67(5):699-704.
• [8]Belge KU, Dayyani F, Horelt A, Siedlar M, Frankenberger M, Frankenberger B, Espevik T, Ziegler-Heitbrock L: The proinflammatory CD14+CD16 + DR++ monocytes are a major source of TNF. J Immunol 2002, 168(7):3536-3542.
• [9]Randolph GJ, Jakubzick C, Qu C: Antigen presentation by monocytes and monocyte-derived cells. Curr Opin Immunol 2008, 20(1):52-60. Epub 2007 Dec 2021
• [10]Grip O, Bredberg A, Lindgren S, Henriksson G: Increased subpopulations of CD16(+) and CD56(+) blood monocytes in patients with active Crohn’s disease. Inflamm Bowel Dis 2007, 13(5):566-572.
• [11]Kawanaka N, Yamamura M, Aita T, Morita Y, Okamoto A, Kawashima M, Iwahashi M, Ueno A, Ohmoto Y, Makino H: CD14+, CD16+ blood monocytes and joint inflammation in rheumatoid arthritis. Arthritis Rheum 2002, 46(10):2578-2586.
• [12]Okamoto H, Mizuno K, Horio T: Circulating CD14+ CD16+ monocytes are expanded in sarcoidosis patients. J Dermatol 2003, 30(7):503-509.
• [13]Waldo SW, Li Y, Buono C, Zhao B, Billings EM, Chang J, Kruth HS: Heterogeneity of Human Macrophages in Culture and in Atherosclerotic Plaques. Am J Pathol 2008, 5:5.
• [14]Rogacev KS, Seiler S, Zawada AM, Reichart B, Herath E, Roth D, Ulrich C, Fliser D, Heine GH: CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease. Eur Heart J 2011, 32(1):84-92.
• [15]Ulrich C, Heine GH, Gerhart MK, Kohler H, Girndt M: Proinflammatory CD14+CD16+ monocytes are associated with subclinical atherosclerosis in renal transplant patients. Am J Transplant 2008, 8(1):103-110. Epub 2007 Nov 2012
• [16]Fabriek BO, Dijkstra CD, van den Berg TK: The macrophage scavenger receptor CD163. Immunobiology 2005, 210(2–4):153-160.
• [17]Moreno JA, Munoz-Garcia B, Martin-Ventura JL, Madrigal-Matute J, Orbe J, Paramo JA, Ortega L, Egido J, Blanco-Colio LM: The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis. Atherosclerosis 2009, 207(1):103-110.
• [18]Fabriek BO, van Bruggen R, Deng DM, Ligtenberg AJ, Nazmi K, Schornagel K, Vloet RP, Dijkstra CD, van den Berg TK: The macrophage scavenger receptor CD163 functions as an innate immune sensor for bacteria. Blood 2009, 113(4):887-892.
• [19]Maniecki MB, Moller HJ, Moestrup SK, Moller BK: CD163 positive subsets of blood dendritic cells: the scavenging macrophage receptors CD163 and CD91 are coexpressed on human dendritic cells and monocytes. Immunobiology 2006, 211(6–8):407-417.
• [20]Mayer A, Lee S, Jung F, Grutz G, Lendlein A, Hiebl B: CD14+ CD163+ IL-10+ monocytes/macrophages: Pro-angiogenic and non pro-inflammatory isolation, enrichment and long-term secretion profile. Clin Hemorheol Microcirc 2010, 46(2–3):217-223.
• [21]Paulsson JM, Held C, Jacobson SH, Lundahl J: In vivo extravasated human monocytes have an altered expression of CD16, HLA-DR, CD86, CD36 and CX(3)CR1. Scand J Immunol 2009, 70(4):368-376.
• [22]Bernhagen J, Krohn R, Lue H, Gregory JL, Zernecke A, Koenen RR, Dewor M, Georgiev I, Schober A, Leng L, et al.: MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 2007, 13(5):587-596.
• [23]Solez K, Colvin RB, Racusen LC, Sis B, Halloran PF, Birk PE, Campbell PM, Cascalho M, Collins AB, Demetris AJ, et al.: Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (‘CAN’). Am J Transplant 2007, 7(3):518-526.
• [24]Merino A, Buendia P, Martin-Malo A, Aljama P, Ramirez R, Carracedo J: Senescent CD14+CD16+ monocytes exhibit proinflammatory and proatherosclerotic activity. J Immunol 2011, 186(3):1809-1815.
• [25]Vincenti F: Current use and future trends in induction therapy. Saudi J Kidney Dis Transpl 2005, 16:506-513.
• [26]Grüllich C, Ziegler C, Finke J: Rabbit anti T-lymphocyte globulin induces apoptosis in peripheral blood mononuclear cell compartments and leukemia cells, while hematopoetic stem cells are apoptosis resistant. Biol Blood Marrow Transpl 2009, 15:173-182.
• [27]Ritter M, Buechler C, Langmann T, Orso E, Klucken J, Schmitz G: The scavenger receptor CD163: regulation, promoter structure and genomic organization. Pathobiology 1999, 67(5–6):257-261.
• [28]Maniecki MB, Etzerodt A, Moestrup SK, Moller HJ, Graversen JH: Comparative assessment of the recognition of domain-specific CD163 monoclonal antibodies in human monocytes explains wide discrepancy in reported levels of cellular surface CD163 expression. Immunobiology 2011, 216(8):882-890.